Yuanfang Liu

State Key Laboratory Of Medical Genomics
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

A First-In-Human Phase 1 Study of a Novel BCMA×CD3 Bispecific T Cell Engager EMB-06 in Relapsed or Refractory Multiple Myeloma.

A First-In-Human Phase 1 Study of a Novel BCMA×CD3 Bispecific T Cell Engager EMB-06 in Relapsed or Refractory Multiple Myeloma.

Journal: American journal of hematology

Published: July 09, 2025

The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma.

The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed/refractory multiple myeloma.

Journal: Blood

Published: June 26, 2025

Efficacy of novel therapies for refractory and relapsed multiple myeloma in China.

Efficacy of novel therapies for refractory and relapsed multiple myeloma in China.

Journal: Chinese medical journal

Published: June 07, 2025

Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma.

Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 22, 2024

Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.

Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.

Journal: BMC medicine

Published: June 23, 2024

Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.

Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.

Journal: British journal of haematology

Published: June 11, 2024

PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.

PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.

Journal: Journal for immunotherapy of cancer

Published: March 18, 2024

Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia.

Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia.

Journal: Blood cancer journal

Published: February 20, 2024

Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.

Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.

Journal: BMC cancer

Published: November 09, 2023

ETV6::ACSL6 translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpression.

ETV6::ACSL6 translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpression.

Journal: Haematologica

Published: August 22, 2023

Metabolically controlled histone H4K5 acylation/acetylation ratio drives BRD4 genomic distribution.

Metabolically controlled histone H4K5 acylation/acetylation ratio drives BRD4 genomic distribution.

Journal: Cell reports

Published: January 04, 2021

Showing 1-11 of 11

Last Updated: 09/26/2026